Envision Pharma Group appoints Head of Envision Value & Access

Envision Pharma Group is pleased to announce the appointment of Mel Formica as its Head of Envision Value & Access.

Envision Pharma Group appoints Head of Envision Value & Access

Oct 03, 2022
Envision Pharma Group appoints Head of Envision Value & Access Image

Mel is a highly respected international life science leader with proven P&L and operational leadership experience, as well as private equity advisory expertise. As an innovator in developing distinctive market entry and commercial strategies that combine customer insight, vision, and creativity, Mel’s work is focused on the forefront of transformations in disruptive technologies, patient-level data, and improved quality of care.

Joining and strengthening an experienced Executive Leadership Team (ELT) at Envision, Mel will drive the growth and expansion of the Value & Access group, pursue service solution innovations, and spearhead the introduction of digital and data analytical capabilities that create impact and deliver value to life science clients.

Meg Heim, Envision’s Chief Executive Officer, said of Mel’s appointment, “Mel’s skillset and experience in industry and consulting aligns closely with our group strategy. His appointment comes at a point where our performance is accelerating and where we continue to drive forward, at pace, in delivering for clients in key strategic areas such as data and digital transformation. I am excited about the innovation, impact, and value he will bring to the talented teams here at Envision, and to our life science clients.”

Mel added, “I am thrilled to be joining Envision at such an exciting time for the group. With a new CEO, ambitions for significant growth, and a drive for greater value and access service and technology integrations, I can’t think of a better time to be joining, supporting the ELT, and advancing the group strategy.”

Close

ISPOR Europe 2022 roundup

The onsite Envision team shares its key takeaways from ISPOR Europe 2022

Achieving Launch Excellence - Oncology

Article

The value of diverse patient representation and engagement in cancer treatment

Whitepaper

ISPOR Europe 2022 roundup

Nov 29, 2022
ISPOR Europe 2022 roundup Image

The Envision Value & Access team shares key takeaways from the ISPOR EU meeting in Vienna earlier this month. You can access the report below.

For more information on how we can support your value and access strategy and communications in an evolving world, contact the team at: value@envisionpharma.com

Access the report


Envision Value & Access unites market access strategy and scientific communications expertise. Collaboration and partnership are at the core of our philosophy, bringing together experts from across Envision Pharma Group, patient collaborators, and client partners to support access to innovative health technologies.

Close

Achieving Launch Excellence - Oncology

Nov 09, 2022
Achieving Launch Excellence - Oncology Image

Any new drug launch must overcome numerous obstacles in the pursuit of success

“Any new drug launch must overcome numerous obstacles in the pursuit of success. Many of these challenges are exacerbated in oncology, where the treatment landscape rapidly evolves with novel mechanisms of actions (e.g., cell therapy, bi/tri-specific antibodies), where there are ever-changing regulatory requirements, the use of biomarkers, etc.” So how does this differ for a small and emerging biotech firm?”

In an article published earlier this year, Envision Pharma Group’s Rachel Shemer, along with Two Labs Angus Bromley and Kimberly Cash, discuss the advantages and challenges smaller companies face.

Close

The value of diverse patient representation and engagement in cancer treatment

Nov 02, 2022
The value of diverse patient representation and engagement in cancer treatment Image

Whitepaper

“To improve outcomes for cancer patients and take advantage of the groundbreaking scientific and technological progress made in oncology prevention, diagnosis, therapy, and care over recent years, it is of crucial importance to ensure all patients with cancer have a role and an ongoing dialogue with the healthcare team.”

Ensuring all patients with cancer have a role and an ongoing dialogue with their healthcare team is crucial.

In a whitepaper published earlier this year Envision Pharma Group’s Rebecca Goldstein, PhD, CMPP, and 90TEN’s Mark Lakeram discuss the value of diverse patient representation and engagement in cancer treatment.

Close

Join Envision Value & Access at ISPOR Europe 2022 to discover how our experts connect your product potential with realized value

Leading global technology-enabled scientific communications company Envision Pharma Group is a platinum sponsor at ISPOR EU 2022, as well as an exhibitor.

Envision Pharma Group and Alucio™ partner to power next-generation scientific exchange for the life science industry

Collaboration capitalizes on Alucio’s flagship Beacon platform and Envision’s global leadership in medical strategy and healthcare communications

Envision Pharma Group and Aktana partner to help medical affairs navigate the evolving physician engagement landscape

HCP demands for more responsive, coordinated engagement across the life sciences organization are driving MSLs to adopt a more agile and value-driven omnichannel approach

Join Envision Value & Access at ISPOR Europe 2022 to discover how our experts connect your product potential with realized value

Oct 13, 2022
Join Envision Value & Access at ISPOR Europe 2022 to discover how our experts connect your product potential with realized value Image

Envision Value & Access is an exhibitor and platinum sponsor at ISPOR EU 2022. As an insight-driven strategic consulting partner for clients and with a full array of HEOR and access services, from the development of your HEOR strategy and RWE roadmap through to evidence generation and communication, we work across functions to develop, communicate, and capture the value of products through a coherent and integrated payer strategy to improve patient access and outcomes globally.

Come meet Suki Kandola, Joe Merkert, and other Envision Value & Access team members at ISPOR Europe 2022, Booth X2-210!
November 6-9; Vienna, Austria

Want to meet at a specific day and time at the event? Then send a message to: Value@envisionpharma.com

Envision Value & Access has the following posters presented at ISPOR Europe 2022:

  • “Deprivation and Access to Care Among Patients with Melanoma in the UK” 
    Vitaccess Ltd: Casey Quinn and Mark Larkin, Pfizer: Ira Jacobs, Envision Pharma Group: Suki Kandola and Karen E. Smoyer
     
  • “A Comparison of the Evolution of Payer Management Practices in Oncology in the United States, Germany, France, and the United Kingdom, Over the Past Five Years”
    Envision Pharma Group: Anne Runyan, Janice Yi, Mounika Bodagala, Milos Pavic, and Thomas Schoenwaelder
     
  • “Investigating How Orphan Drug Manufacturers Can Optimize Clinical Trial Design so Patients across Geographies Can Access Life-Saving Innovations​”
    Envision Pharma Group: Sheli Goldstein, Anne Runyan, Joe Merkert, Thomas Schoenwaelder, and Milos Pavic
Close

Envision Pharma Group and Alucio™ partner to power next-generation scientific exchange for the life science industry

Oct 06, 2022
Envision Pharma Group and Alucio™ partner to power next-generation scientific exchange for the life science industry Image

Envision Pharma Group (Envision) and Alucio today announced a global partnership to power impactful, scientific exchange and deliver additional value for life science customers.

By combining Alucio’s innovative Beacon scientific exchange platform and technology with Envision’s extensive medical affairs experience and scientific content development expertise, a broader set of life science companies will have the ability to assemble, refine, and adapt their scientific content with ease. Beacon is a modern content activation and healthcare professional engagement platform built specifically for medical science liaisons, medical affairs professionals, and market access teams.

Through this collaboration, Envision will provide strategic, insight-driven communications expertise with agile content development approaches to assist medical affairs and market access teams in taking full advantage of the Beacon platform and future Alucio technology products.

More broadly, this global partnership has the potential to transform current industry standards in stakeholder engagement by redefining best practice content development processes and leveraging technology to create powerful, personalized scientific exchanges. Through a user-centric approach, the companies will seek to enhance and integrate technology solutions that deliver real-time data and analytics to inform strategy and aid customer decision-making.

“Envision is a recognized, global leader within the medical affairs space. We are very excited about the potential of this partnership to bring the benefits of our modern scientific exchange platform to an even broader network and establish best practice in the context of content development, deployment, and engagement,” said Dave Gulezian, Alucio Co-Founder and Chief Executive Officer. “We also look forward to collaborating to identify new opportunities to address emerging customer needs.”

Envision’s Chief Executive Officer, Meg Heim, added, “We have been impressed with what Alucio has built with Beacon and the momentum they have generated within the medical affairs space. We’re equally excited to align our medical strategy, agile content development, and communications expertise with Alucio’s technology capabilities to further enhance our customers’ stakeholder engagement through a personalized, omnichannel approach.”

 

 

Close

Envision Pharma Group and Aktana partner to help medical affairs navigate the evolving physician engagement landscape

Sep 27, 2022
Envision Pharma Group and Aktana partner to help medical affairs navigate the evolving physician engagement landscape Image

Envision Pharma Group, a global, technology-enabled scientific communications company operating across many areas of medical affairs, and Aktana, the leader in intelligent customer engagement for the life sciences industry, have announced a strategic partnership that provides medical teams with a comprehensive toolkit for more impactful scientific exchange.

By bringing together their extensive technical and industry expertise, Envision and Aktana offer life science companies the ability to enable their medical science liaisons (MSLs) to address healthcare professionals’ (HCPs) demands for personalized, scientifically relevant content, and coordinated omnichannel engagement.

Despite the industry’s separation between commercial and medical teams, today’s HCPs expect MSLs to operate with a holistic view of their engagement with the product. While many life sciences companies have already started equipping commercial teams with technology to synthesize data and coordinate interactions across channels, medical affairs organizations still largely lack the right tools to navigate the dual challenges of information overwhelm and decreasing HCP access. 

“MSLs are in a challenging position, learning to balance traditional and modern digital strategies to engage with physicians in an environment where they are asked to respond to questions faster and more frequently,” said Derek Choy, president of Aktana. “With Envision, we can help MSLs by optimizing their HCP engagements to be more relevant, coordinated, and tailored to their individual needs, whether digital or in-person.”

Together, Envision and Aktana will provide medical affairs teams with streamlined, tailored solutions that incorporate Envision’s industry-leading scientific expertise with Aktana’s intelligence platform, which is fueled by a range of integrated data sources and learns from every prior interaction. The partnership arms MSLs with quick, reliable access to the latest scientific information that’s relevant to each HCP, paired with data-driven insights on how, when, and where to deliver that information for optimal customer engagement. 

“Like us, Aktana has a long history of helping life sciences companies of all sizes break down data silos, connect internal teams, and generate insights to improve interactions with HCPs,” said Paul Archer, Chief Commercial Strategy Officer at Envision. “Together, we will focus on guiding medical affairs teams to build, deploy, and refine their omnichannel strategies so MSLs can deliver value to HCPs when they need it most for improved patient outcomes.” 

Archer continued, “We look forward to a long-term partnership with Aktana, as we take the next steps toward our combined vision for a powerful solution that incorporates all touchpoints across the HCP journey.”

Close

Envision Pharma Group appoints new CEO

Meg Heim named as its new Chief Executive Officer

Envision partners with Vitaccess for patient engagement webinar

Envision Pharma Group partners with scite to display Smart Citations in iEnvision® – the global medical affairs platform

Smart Citations will feature in Library, Datavision®, and Scientific Communication Platform modules

Envision Pharma Group appoints new CEO

Sep 21, 2022
Envision Pharma Group appoints new CEO Image

Envision Pharma Group is pleased to announce the appointment of Meg Heim as its new Chief Executive Officer. Meg is an accomplished business leader with strong leadership experience, and an established reputation within Pharmaceutical, Medical Device and Health Technology markets. Throughout her career she has championed the professionalism of medical affairs and the innovations that improve patient experience.

Working closely with a strong and experienced Executive Leadership Team, Meg will be responsible for delivering an ambitious five-year plan that will reinforce Envision as the global leader in scientific and commercialization strategy and solutions; medical affairs; and lifecycle planning enabled by leading technology solutions and world-class people.

Meg joins Envision at a pivotal moment, with Group performance accelerating as it continues to deliver a compelling combination of technology and services to clients. Envision’s strategy and innovation has ensured the company continues to serve and anticipate its clients’ evolving needs. Meg replaces David Thompson, who steps down as CEO to pursue other opportunities, including in the not-for-profit sector at a cancer charity, after more than six years with Envision Pharma Group and over 25 years in the industry.

Brian Hepburn Executive Co-Chair of Envision Pharma Group said: “I am truly excited by the appointment of Meg as our new Chief Executive Officer. Meg has an established track record within the healthcare industry and brings with her a deep understanding of medical affairs which will be highly complementary to the existing expertise within the business. This is an exciting time for Envision as we continue to accelerate innovation and work towards our vision of improving lives through the power of our technology and expertise.”

Meg said: “I am energized to be joining Envision Pharma Group at such an important time in the industry. I see a clear opportunity for further growth building off established and new opportunities in the sector. The company has an exceptional team and client base, and I am looking forward to spending time with our people, our clients, and other key partners.”

Close

Envision partners with Vitaccess for patient engagement webinar

Jun 28, 2022
Envision partners with Vitaccess for patient engagement webinar Image

Following the announcement in March of our Vitaccess partnership that is designed to power evidence generation for the biopharmaceutical industry, we are thrilled to be collaborating with Vitaccess on its “Keeping it real” webinar series.

On July 20, Envision’s Dawn Lobban, Global Lead, Patient Partnerships from Envision the Patient, will join Dr. Catherine Bottomley, Chief Scientific Officer from Vitaccess, to discuss patient engagement in the publication of real-world evidence (RWE). Secure your seat here in order to listen to two engaging and passionate speakers cover patient engagement and RWE.

Close

Envision Pharma Group partners with scite to display Smart Citations in iEnvision® – the global medical affairs platform

Jun 07, 2022
Envision Pharma Group partners with scite to display Smart Citations in iEnvision® – the global medical affairs platform Image

Technology-enabled scientific communications company Envision Pharma Group (“Envision” or the “Company”) today announced Library, Datavision, and Scientific Communication Platform (SCP) modules will now feature Smart Citations from scite, an award-winning tool that helps students and researchers discover and understand research findings better.

Fully integrated into the publication details held within Library, Datavision, and SCP modules, Smart Citation badges provide regularly updated, at-a-glance views of how research has been cited and permits click-through access to the scite website for more detailed information on the article. This new functionality sits alongside and enhances the existing article-level metrics provided in iEnvision through integrations with Altmetric and Scopus.

Russell Traynor, Envision’s Global Head, iEnvision Platform Strategy, and former chair of the International Society of Medical Publication Professionals, said, “We are excited to announce this collaboration and hope that the addition of Smart Citations to Library, Datavision, and SCP will provide additional insights and value to the users of our solutions.”

Dr. Josh Nicholson, Chief Executive Officer of scite, added, “We’re very happy to be working with Envision to provide a powerful integration between the two platforms. Smart Citations are already used by various pharmaceutical companies and communications agencies and we’re happy to surface them in Library for a more streamlined workflow.”

About Envision Pharma Group

Founded in 2001, Envision Pharma Group is a global, technology-enabled scientific communications company serving pharmaceutical, biotechnology, and medical device companies. As a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility, Envision provides scientific communication services and technology solutions to more than 90 companies, including 19 of the top 20 pharmaceutical companies. Learn more at: www.envisionpharmagroup.com

About scite

scite is a Brooklyn-based start-up that helps researchers discover and evaluate scientific articles better through Smart Citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by researchers from around the world and is funded in part by the National Science Foundation and the National Institute of Drug Abuse of the National Institutes of Health. Learn more at: scite.ai

About iEnvision Library

Library, built on the iEnvision medical project management platform, serves as a central repository for the enterprise-wide storage and sharing of final, approved scientific and medical materials such as publications and slide decks. Embedding Smart Citation in Library allows an at-a-glance view of the total number of times a paper has been cited and the context of these citations. Learn more at: www.envisionpharmagroup.com/technology/ienvision-library

About iEnvision Datavision®

The iEnvision Datavision module is designed to drive the compliant and efficient management of scientific and medical publications. With role-specific dashboards, publication managers can access the detailed information needed to start and manage publications. Containing built-in checklists and system validation, it ensures publications comply with Good Publication Practice and the International Committee of Medical Journal Editors (ICMJE) requirements. Learn more at: www.envisionpharmagroup.com/technology/datavision

About iEnvision Scientific Communication Platform

iEnvision’s SCP is a centralized medical affairs solution, linking key scientific themes and statements to product-related assets such as publications, slides, and videos. The common template of SCP themes, key statements, and supporting statements maintains simple user navigation and a standardized approach to the formatting and development of SCPs – with a lexicon designed to ensure a consistent use of language that includes preferred and prohibited terms. Learn more at: www.envisionpharmagroup.com/technology/scientific-communication-platform-module

Close

Envision Pharma Group expands capabilities with specialist behavioral science offering Envision the Change

Envision Pharma Group and Vitaccess create a global partnership to power evidence generation for the biopharmaceutical industry

Move combines Envision’s global leadership position in medical affairs communications with Vitaccess’ award-winning capabilities in real-world evidence (RWE)

Paul Archer promoted to Chief Commercial Strategy Officer

Envision Pharma Group expands capabilities with specialist behavioral science offering Envision the Change

Apr 05, 2022
Envision Pharma Group expands capabilities with specialist behavioral science offering Envision the Change Image

Leading global technology-enabled scientific communications company Envision Pharma Group has launched a suite of behavioral science-led solutions to expand the group’s capabilities and optimize value offering to its clients.

Envision the Change is spearheaded by Mark Lakeram (Global Lead, Behavioral Science) and supported by Directors Jenny Squibbs (in the UK) and Justine Swann (in the US). As a dedicated team of behavioral scientists, they understand that to affect real change the intricacies and realities of everyday life and health need to be considered.

Lakeram said, “All healthcare decisions are influenced by human behavior. By taking into account the science behind this, our proprietary Feel-Think-DoTM model helps to decode why people make the decisions they do. From strategic and tactical planning, to aiding information recall through data visualization and adult learning techniques – we provide counsel and support to drive behavior change that ultimately improves health outcomes.”

Susanne Clark, Head of Envision Scientific Solutions, added, “No matter what product challenges are ahead, understanding the behavior of key stakeholders will be paramount. I’m delighted that we’ve strengthened our service offering with Envision the Change in order to support our clients across all aspects of medical affairs and marketing, from planning to creative implementation for both external and internal audiences.”

Close

Envision Pharma Group and Vitaccess create a global partnership to power evidence generation for the biopharmaceutical industry

Mar 21, 2022
Envision Pharma Group and Vitaccess create a global partnership to power evidence generation for the biopharmaceutical industry 
 Image

Technology-enabled scientific communications company Envision Pharma Group (“Envision” or the “Company”) has announced a partnership with Vitaccess, an innovative research organization.

The Envision and Vitaccess partnership will bring a full-service, customizable approach to data gathering, insight generation, and scientific communications that will stand up to the nuances, scale, and challenges of any client setting.

Acknowledging that every client need is unique, this collaboration will help leverage patient-centric digital solutions to gather data quickly, flexibly, and at scale, and incorporate patients’ “lived experience” – insights which are often insufficiently integrated into the design and implementation of many RWE studies published globally.

The complexities in bringing a product to market cannot be underestimated. An increasing requirement for data leads to a growing need for more adaptive RWE research to be generated and communicated to regulators, pre and post approval. Envision and Vitaccess understand these additional demands placed on their biopharma clients, and the need to maximize value and access to their products through timely, insightful evidence generation which communicates the real-world impact of diseases and their treatments on patients.

Paul Archer, Envision Chief Commercial Strategy Officer, said, “This collaboration offers clients a really powerful toolbox to accelerate, scale, and publish their evidence-generation activities. We admire Vitaccess’ innovative, inclusive digital approach to designing patient-centric RWE studies, and whose flexible solutions provide access to outcomes measures that serve regulators, payers, and health systems all over the world.”

Dr. Mark Larkin, CEO and Founder of Vitaccess, commented, “Combining our Vitaccess Real™ real-time RWE platform and expertise in patient-centric research with Envision’s established leadership in medical affairs and communications brings clients a unique, full-service offering for engaging with patients and caregivers globally.”

Close

Paul Archer promoted to Chief Commercial Strategy Officer

Feb 18, 2022
Paul Archer promoted to Chief Commercial Strategy Officer Image

Leading global technology-enabled scientific communications company Envision Pharma Group has promoted Paul Archer to Chief Commercial Strategy Officer (CCSO).

In his new role, Archer will lead the development of an integrated commercial group strategy to drive continued revenue growth through service synergies and the implementation of new services. This is a newly defined position that reflects the continued expansion of Envision and its goals of being the global medical affairs partner of choice and to transform the pharma industry, ultimately leading to life-changing outcomes.

Working across the group, Archer will leverage Envision’s unique combination of technology and service capabilities to meet the evolving needs of its medical affairs clients and ensure it continues to lead the way in bringing innovative solutions to the market.

On his appointment that also sees Archer join Envision’s Executive Leadership Team, he said, “I am thrilled to be taking on this role. Envision is full of purpose-driven, talented people who thrive on delivering impactful, often award-winning work for our clients and their patients. I am genuinely excited to be able to apply my 20 years of strategic and commercial experience to drive a successful integrated commercial group for Envision and to realize the opportunities and value this creates for our clients, patients, talent, and Envision as a whole.”

David Thompson, CEO, Envision Pharma Group, added, “Paul has been a strong addition to Envision since he joined a year ago, and he will now lead a growing mandate as Chief Commercial Strategy Officer as we continue to exploit synergies across our four verticals of scientific services, technology, emerging biotech, and value – as well as uncover new service offerings through investment and acquisition that can help us improve our partnership strength with clients.”

Close